Donuts, Whatever was found in the data probably would have forced a new Phase III trial to be run which would cost quite a few M's of $'s and would be risky in the case of Ovarian cancer. The process and drug(s) might now be the issue but what their potential is - make a difference (in cancer). So, they made the right decision and took the final HIT on V and Ovarian cancer. The market is ignoring all other possibilities for now. My real "dream" is that Merck buys the whole company for $1B and takes the cash, the pipeline, the application and avoids making any more payments to Endocyte. Otherwise, we have a long wait here and should bottom at $6 or so.
Assuming 4 types of Data outcome of NSCLC (1)Good (2)Better (3)Best (4) Super Blockbuster. If Blockbuster or Best Endocyte will not Sell company. If Good or Better then 1B mark is pretty good to Sell company.